stockrow
Saturday 7 November 2026
Export LABT’s income statement to Excel — free account
Lakewood-Amedex Biotherapeutics Inc.
LABT Healthcare Biotechnology
0.37
0.17
−31.48%
Follow LABT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (5) | (4) | (6) | (20.8%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (5) | (4) | (9) | (20.8%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (9.92) | (8.40) | (7.90) | (15.3%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (8.28) | (2.79) | (3.46) | (66.3%) | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (8.29) | (2.79) | (3.46) | (66.3%) | ||||||
| Book value | — | — | — | — | — | — | — | — | 0.59 | (2.82) | 3.05 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 1 | 1 | +0.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (6) | (2) | (5) | (66.0%) | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (6) | (2) | (5) | (66.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 0 | (2) | 4 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | — | (1) | 0 | (5) | (65.3%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 0 | (2) | 4 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (753.49) | (302.50) | (753.5) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 749.24 | 0.00 | +749.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 5 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Lakewood-Amedex Biotherapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABPO Abpro Holdings Inc. | $1.4M | 0.5× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $1.4M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| ELAB PMGC Holdings Inc. | $1.3M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $1.3M | — | — | 0.00% | — | −0.32% | 0.00% | 0.00% |